CLINICAL TRIALS PROFILE FOR FUROSCIX
✉ Email this page to a colleague
All Clinical Trials for FUROSCIX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04161482 ↗ | An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability | Completed | Clinical Trial Data Services, Inc. | Phase 1 | 2019-12-02 | This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix. |
| NCT04161482 ↗ | An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability | Completed | CSSi Life Sciences | Phase 1 | 2019-12-02 | This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix. |
| NCT04161482 ↗ | An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability | Completed | scPharmaceuticals, Inc. | Phase 1 | 2019-12-02 | This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix. |
| NCT05528588 ↗ | Furoscix in Heart Failure Patients With Diuretic Resistance | Not yet recruiting | scPharmaceuticals, Inc. | Phase 2 | 2022-10-01 | This will be a randomized, open-label pilot study of 60 patients with and without diuretic resistance who were recently admitted and discharged for acute decompensated heart failure with and oral furosemide regimen testing whether Furoscix is more effective at achieving post-discharge outpatient diuresis than standard of care. Diuretic resistance will be identified using the BAN-ADHF (BUN, creAtinine, NP-levels, Age, Diabetes and DBP, HF hospitalization, and atrial Fibrillation) score which has been integrated into the electronic health record. The score is integer-based with a score of > 11 indicating diuretic resistance with high likelihood of poor outcomes. The primary outcome is spot urine sodium at 1 hour, 4 hours, and 8 hours post-treatment. |
| NCT05528588 ↗ | Furoscix in Heart Failure Patients With Diuretic Resistance | Not yet recruiting | University of Texas Southwestern Medical Center | Phase 2 | 2022-10-01 | This will be a randomized, open-label pilot study of 60 patients with and without diuretic resistance who were recently admitted and discharged for acute decompensated heart failure with and oral furosemide regimen testing whether Furoscix is more effective at achieving post-discharge outpatient diuresis than standard of care. Diuretic resistance will be identified using the BAN-ADHF (BUN, creAtinine, NP-levels, Age, Diabetes and DBP, HF hospitalization, and atrial Fibrillation) score which has been integrated into the electronic health record. The score is integer-based with a score of > 11 indicating diuretic resistance with high likelihood of poor outcomes. The primary outcome is spot urine sodium at 1 hour, 4 hours, and 8 hours post-treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FUROSCIX
Condition Name
Clinical Trial Locations for FUROSCIX
Trials by Country
Clinical Trial Progress for FUROSCIX
Clinical Trial Phase
Clinical Trial Sponsors for FUROSCIX
Sponsor Name
